Empagliflozin

Jardiance, INN-Empagliflozin

Empagliflozin: Novel antidiabetes and pro-cardiac drug

Empagliflozin has been shown to improve glycaemic control and reduce CV mortality along with salutary effects on renal outcomes as compared to placebo in a recently conducted EMPA-REG OUTCOME trial in a large number of patients.[1,2] In this study, more than 7000 patients were randomly assigned to receive empagliflozin in the dose of 10 mg or 25 mg or placebo once daily. Patients were followed ...

Empagliflozin and the Prevention of Heart€Failure

SEE PAGE 347 H eart failure develops in more than 1 in 5 patients with diabetes mellitus (DM) older than 65 years of age and augers an extremely poor prognosis, with a median survival of approximately 4 years. The landmark EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) showed that empagliflozin significantly reduced the primary composite...

Impact of empagliflozin on diabetic kidney disease

Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule-glomerular feedback, thereby protect against diabetes-induced caidio-renal injuries.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

BACKGROUND The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovas...